Atlas Venture Fund Xi, L.p. - Net Worth and Insider Trading

Atlas Venture Fund Xi, L.p. Net Worth

The estimated net worth of Atlas Venture Fund Xi, L.p. is at least $470 Million dollars as of 2024-05-14. Atlas Venture Fund Xi, L.p. is the 10% Owner of Dyne Therapeutics Inc and owns about 8,050,704 shares of Dyne Therapeutics Inc (DYN) stock worth over $227 Million. Atlas Venture Fund Xi, L.p. is the 10% Owner of Day One Biopharmaceuticals Inc and owns about 8,984,019 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $149 Million. Atlas Venture Fund Xi, L.p. is also the 10% Owner of Akero Therapeutics Inc and owns about 3,974,858 shares of Akero Therapeutics Inc (AKRO) stock worth over $81 Million. Besides these, Atlas Venture Fund Xi, L.p. also holds Third Harmonic Bio Inc (THRD) , Xilio Therapeutics Inc (XLO) , Ikena Oncology Inc (IKNA) . Details can be seen in Atlas Venture Fund Xi, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Atlas Venture Fund Xi, L.p. has not made any transactions after 2024-02-28 and currently still holds the listed stock(s).

Transaction Summary of Atlas Venture Fund Xi, L.p.

To

Atlas Venture Fund Xi, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Atlas Venture Fund Xi, L.p. owns 7 companies in total, including Dyne Therapeutics Inc (DYN) , Akero Therapeutics Inc (AKRO) , and Ikena Oncology Inc (IKNA) among others .

Click here to see the complete history of Atlas Venture Fund Xi, L.p.’s form 4 insider trades.

Insider Ownership Summary of Atlas Venture Fund Xi, L.p.

Ticker Comapny Transaction Date Type of Owner
DYN Dyne Therapeutics Inc 2024-02-28 10 percent owner
AKRO Akero Therapeutics Inc 2019-06-24 10 percent owner
IKNA Ikena Oncology Inc 2021-12-14 10 percent owner
2024-02-08 10 percent owner
2022-06-17 10 percent owner
2022-09-19 10 percent owner
2023-11-03 10 percent owner

Atlas Venture Fund Xi, L.p. Latest Holdings Summary

Atlas Venture Fund Xi, L.p. currently owns a total of 6 stocks. Among these stocks, Atlas Venture Fund Xi, L.p. owns 8,050,704 shares of Dyne Therapeutics Inc (DYN) as of February 28, 2024, with a value of $227 Million and a weighting of 48.22%. Atlas Venture Fund Xi, L.p. owns 8,984,019 shares of Day One Biopharmaceuticals Inc (DAWN) as of June 17, 2022, with a value of $149 Million and a weighting of 31.76%. Atlas Venture Fund Xi, L.p. also owns 3,974,858 shares of Akero Therapeutics Inc (AKRO) as of June 24, 2019, with a value of $81 Million and a weighting of 17.16%. The other 3 stocks Third Harmonic Bio Inc (THRD) , Xilio Therapeutics Inc (XLO) , Ikena Oncology Inc (IKNA) have a combined weighting of 2.87% among all his current holdings.

Latest Holdings of Atlas Venture Fund Xi, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DYN Dyne Therapeutics Inc 2024-02-28 8,050,704 28.16 226,707,825
DAWN Day One Biopharmaceuticals Inc 2022-06-17 8,984,019 16.62 149,314,396
AKRO Akero Therapeutics Inc 2019-06-24 3,974,858 20.30 80,689,617
THRD Third Harmonic Bio Inc 2022-09-19 594,096 12.91 7,669,779
XLO Xilio Therapeutics Inc 2024-02-08 2,754,109 1.09 3,001,979
IKNA Ikena Oncology Inc 2021-12-14 2,116,569 1.33 2,815,037

Holding Weightings of Atlas Venture Fund Xi, L.p.


Atlas Venture Fund Xi, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Atlas Venture Fund Xi, L.p. has made a total of 4 transactions in Dyne Therapeutics Inc (DYN) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in Dyne Therapeutics Inc is the sale of 807,838 shares on February 28, 2024, which brought Atlas Venture Fund Xi, L.p. around $20 Million.

According to the SEC Form 4 filings, Atlas Venture Fund Xi, L.p. has made a total of 2 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the acquisition of 766,667 shares on June 17, 2022, which cost Atlas Venture Fund Xi, L.p. around $12 Million.

According to the SEC Form 4 filings, Atlas Venture Fund Xi, L.p. has made a total of 1 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akero Therapeutics Inc is the acquisition of 270,000 shares on June 24, 2019, which cost Atlas Venture Fund Xi, L.p. around $4 Million.

More details on Atlas Venture Fund Xi, L.p.'s insider transactions can be found in the Insider Trading History of Atlas Venture Fund Xi, L.p. table.

Insider Trading History of Atlas Venture Fund Xi, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Atlas Venture Fund Xi, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Atlas Venture Fund Xi, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atlas Venture Fund Xi, L.p. is -5.92%. GuruFocus also compares Atlas Venture Fund Xi, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Atlas Venture Fund Xi, L.p. within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Atlas Venture Fund Xi, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Atlas Venture Fund Xi, L.p.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.91
Relative Return to S&P 500(%) 6.14

Atlas Venture Fund Xi, L.p. Ownership Network

Ownership Network List of Atlas Venture Fund Xi, L.p.

No Data

Ownership Network Relation of Atlas Venture Fund Xi, L.p.


Atlas Venture Fund Xi, L.p. Owned Company Details

What does Dyne Therapeutics Inc do?

Who are the key executives at Dyne Therapeutics Inc?

Atlas Venture Fund Xi, L.p. is the 10 percent owner of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include Chief Medical Officer Wildon Farwell , See Remarks Richard William Scalzo , and See Remarks Oxana Beskrovnaya .

Dyne Therapeutics Inc (DYN) Insider Trades Summary

Over the past 18 months, Atlas Venture Fund Xi, L.p. made 4 insider transaction in Dyne Therapeutics Inc (DYN) with a net sale of 884,198. Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 241,325 shares made by Jonathan Mcneill , a net sale of 191,946 shares made by Richard William Scalzo , and a net sale of 1,171,794 shares made by Joshua T Brumm .

In summary, during the past 3 months, insiders sold 4,515,887 shares of Dyne Therapeutics Inc (DYN) in total and bought 0 shares, with a net sale of 4,515,887 shares. During the past 18 months, 5,472,903 shares of Dyne Therapeutics Inc (DYN) were sold and 3,583,447 shares were bought by its insiders, resulting in a net sale of 1,889,456 shares.

Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Dyne Therapeutics Inc Insider Transactions

No Available Data

Atlas Venture Fund Xi, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Atlas Venture Fund Xi, L.p.. You might contact Atlas Venture Fund Xi, L.p. via mailing address: 400 Technology Square, 10th Floor, Cambridge Ma 02139.

Discussions on Atlas Venture Fund Xi, L.p.

No discussions yet.